Work

Marked QTc Interval Prolongation Associated With Dronedarone in Paroxysmal Atrial Fibrillation and No Structural Disease

Year: 2025

Type: article

Abstract: Dronedarone, a multichannel antiarrhythmic drug, was developed as a safer alternative to amiodarone for atrial fibrillation. Although initially considered to have a lower proarrhythmic risk, post-marketing data and clinical experience suggest otherwise. We describe the case of a 44-year-old male with paroxysmal atrial fibrillation and no structural heart disease who developed marked QTc prolongation while receiving dronedarone, despite being asymptomatic. This case highlights the potential for clinically silent but significant QTc prolongation during dronedarone therapy, underscoring the importance of careful ECG monitoring, even in low-risk patients.

Source: Cureus

DOI: 10.7759/cureus.99543

Authors: Sebastian Hernandez Mejia, Joud Fahed, Rayna Isber, Nidal Isber

Institutions: Richmond University Medical Center, Saint Agnes Hospital, Ascension, Columbia University, Barnard College

Language: English

Topic: Cardiac electrophysiology and arrhythmias

Subfield: Cardiology and Cardiovascular Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: diamond

OpenAlex ID: W4417464605